MaxCyte, Inc. Grant of Options (1371L)
September 28 2016 - 1:00PM
UK Regulatory
TIDMMXCT
RNS Number : 1371L
MaxCyte, Inc.
28 September 2016
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Gaithersburg, MD, 28 September 2016 - MaxCyte (LSE: MXCT), an
established and revenue generating US-based developer and supplier
of cell engineering technology to biotechnology and pharmaceutical
firms engaged in cell therapy, drug discovery and development,
biomanufacturing, gene editing and immuno-oncology, announces that
it granted options over a total of 140,000 shares of its common
stock ("Common Stock") to certain employees of the Company ("Option
Grants"). None of the Option Grants were provided to Directors or
Persons Discharging Management Responsibilities ("PDMRs").
The Option Grants vest ratably on a monthly basis following
grant, generally over 48 months. The Option Grants have an exercise
period of 10 years from date of grant, at which time they will
expire. All the grants are effective of today, at an exercise price
of 85.0p per option.
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering products and services to
biopharmaceutical firms engaged in cell therapy, drug discovery and
development, biomanufacturing, gene editing and immuno-oncology
markets, which independent market analyses estimate to be, in
aggregate, in excess of $35 billion in 2015. The Company's patented
flow electroporation technology enables its products to deliver
fast, reliable and scalable cell engineering to drive the research
and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, clinical and
commercial grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is
developing CARMA, its proprietary platform in immuno-oncology, to
deliver a validated non-viral approach to CAR therapies across a
broad range of cancer indications, including solid tumors where
existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKNPADXKEFF
(END) Dow Jones Newswires
September 28, 2016 13:00 ET (17:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024